Risperidone Market Report 2025

The risperidone market size has grown strongly in recent years. It will grow from $7.13 billion in 2024 to $7.7 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth during the historic period was driven by the increasing prevalence of schizophrenia and bipolar disorder, rising awareness of mental health conditions, greater adoption of atypical antipsychotics over conventional drugs, expansion of psychiatric clinics and hospitals, and the growing number of geriatric populations prone to psychiatric conditions.

The risperidone market size is expected to see strong growth in the next few years. It will grow to $10.35 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth during the forecast period is fueled by rising demand for long acting injectable formulations, increasing incidence of pediatric and adolescent psychiatric disorders, greater focus on personalized medicine in psychiatry, wider use of risperidone in combination therapies, and expanding healthcare expenditure in emerging markets. The primary trends in the forecast period include the development of combination therapies, integration with digital health platforms, adoption in telepsychiatry services, innovation in delivery methods, and the introduction of cost effective generics.

The rising prevalence of mental health disorders is expected to drive the growth of the risperidone market. Mental health disorders encompass a wide range of conditions that affect mood, thinking, and behavior, leading to significant distress and disruption in daily functioning. The increasing rates of these disorders are largely due to heightened stress levels and changes in modern lifestyles, which affect emotional balance, sleep patterns, and overall mental well-being. Risperidone is commonly used to manage mental health conditions by regulating neurotransmitters in the brain, which helps reduce symptoms such as agitation, hallucinations, and mood swings, thus promoting emotional stability. For example, in March 2024, the House of Commons Library reported a rise in mental health disorders among 17- to 19-year-olds, with the proportion increasing from 17% in 2021 to 26% in 2022. As mental health issues continue to grow, the demand for risperidone is expected to increase.

Companies in the risperidone market are focusing on developing advanced treatment solutions, such as long-acting injectable formulations, to enhance patient adherence and improve treatment outcomes. Long-acting injectables are medications designed to release risperidone gradually over time, requiring less frequent dosing while maintaining consistent therapeutic effects. For example, in January 2023, Luye Pharma Group Ltd., a pharmaceutical company based in China, received approval from the U.S. Food and Drug Administration (FDA) for Rykindo (risperidone), an extended-release injectable formulation. This treatment is used for managing schizophrenia and as adjunctive therapy with lithium or valproate in the maintenance treatment of bipolar I disorder in adults. The biweekly intramuscular injection is developed using Luye Pharma’s microsphere technology, allowing for sustained release to maintain symptom control. The formulation offers rapid symptom relief and flexibility for physicians to adjust treatment based on patient needs, improving overall treatment adherence.

In January 2025, Lyndra Therapeutics Inc., a clinical-stage biopharmaceutical company based in the U.S., partnered with Thermo Fisher Scientific to advance long-acting oral therapies, including weekly oral risperidone. This partnership is aimed at transforming the way patients take their medication, by enabling the large-scale manufacturing and clinical trial support necessary to bring long-acting oral therapies, such as weekly oral risperidone, to broader markets. Thermo Fisher Scientific is a leading company in the production of risperidone and will support Lyndra Therapeutics in developing innovative oral therapies to improve patient compliance and treatment outcomes.

Major players in the risperidone market are Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Sun Pharmaceutical Industries Ltd., Apotex Inc., Cipla Limited., Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Zydus Cadila Healthcare Ltd, Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Natco Pharma Limited., Strides Pharma Science Limited., RPG Life Sciences Limited., Jubilant Cadista Pharmaceuticals Inc., ICROM S.p.A., Accord Healthcare Ltd., Ambica Pharma Machines Pvt. Ltd., Gonane Pharma Private Limited., Janssen Pharmaceuticals, LGM Pharma.

North America was the largest region in the risperidone market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in risperidone report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the risperidone market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

Risperidone is an atypical antipsychotic medication used to manage mental health disorders such as schizophrenia, bipolar disorder, and irritability linked to autism. It functions by balancing key neurotransmitters in the brain, particularly dopamine and serotonin, to improve mood, thought processes, and behavior.

The primary product types of risperidone are tablets, oral solution, and injectable. Tablets are an oral form of risperidone used to treat conditions such as schizophrenia, bipolar disorder, and irritability associated with autism by helping regulate neurotransmitter activity in the brain. Risperidone is administered across different patient groups, including pediatric, adult, and elderly populations. It is applied in therapeutic areas such as schizophrenia, bipolar disorder, autism, and other related conditions. Distribution occurs through multiple channels, including hospital pharmacies, retail pharmacies, online pharmacies, and clinic pharmacies, serving end users such as hospitals, homecare, specialty clinics, ambulatory surgical centers, and others.

The risperidone market research report is one of a series of new reports that provides risperidone market statistics, including the risperidone industry's global market size, regional shares, competitors with a risperidone market share, detailed risperidone market segments, market trends and opportunities, and any further data you may need to thrive in the risperidone industry. This risperidone market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The risperidone market consists of sales of orally disintegrating tablets, oral syrups, injectable long-acting formulations, combination formulations, and extended-release tablets. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.